We may be winning the war on death from infectious diseases but we now face a greater threat from non-communicable diseases, writes Steve Davis
OVER the last 25 years, thanks partly to a co-ordinated global effort to fight infectious diseases, including malaria, tuberculosis (TB), HIV/Aids, and polio, childhood mortality rates have been reduced by 50%, and average life expectancy has increased by more than six years.
Moreover, the share of the world’s population living in extreme poverty has been halved. These are major achievements, but they have brought a new set of challenges that must urgently be addressed.
As lives have gotten longer and lifestyles have changed, non-communicable diseases (NCDs) such as diabetes, cardiovascular disease, cancer, and respiratory ailments have taken hold, becoming far and away the world’s leading causes of death.
While about 3.2m people died from malaria, TB, or HIV/Aids in 2014, more than 38m died from NCDs. And the death toll continues to rise.
Consider diabetes, one of the fastest-growing NCDs. According to a recent World Health Organization (WHO) report, diabetes killed 1.5m people in 2012, about the same number as TB. But while TB deaths have declined by half since 1990, the impact of diabetes is rising fast.
In 1980, 108m people were living with diabetes, a rate of about one person in 20; today, more than 400m, or one in 12, have the disease.
Contrary to popular perception of NCDs as diseases of the affluent, they disproportionately affect the poor in countries at all stages of economic development, but especially low- and middle-income countries.
Indeed, according to the WHO report, more than 80% of diabetes-related deaths occur outside the high-income countries.
One reason for this is that type 2 diabetes, the more common variant, is associated with lifestyle factors, such as inactivity, obesity, poor diet, and smoking, that are often more common among the less affluent.
Making matters worse, in the poorer communities of the world, the tools and medicines to diagnose and treat diabetes are scarce and often priced beyond people’s means.
A recent study authored by Path, with support from Novo Nordisk, showed that, in some cases, just one third of public health facilities had insulin in stock, and only one in four had testing strips available to monitor diabetes.
In Ghana, 15 days’ wages pays for a 30-day supply of just two of the drugs needed to prevent complications.
These failings mean that almost half of diabetes cases outside wealthy countries are undiagnosed or inadequately managed. This has significant human and economic consequences.
Diabetes requires lifelong treatment, and the earlier it is detected and care begins, the better the outcome. Untreated, diabetes causes conditions that make it impossible to work and often lead to early death.
What will it take to ensure that people have the tools and medicines to diagnose, treat, and monitor diabetes?
For starters, policymakers and donors must acknowledge the disproportionate impact of diabetes on poor communities and focus greater attention and funding on prevention and treatment.
Prevention programmes that promote healthier diets and exercise can lower the prevalence of type 2 diabetes and reduce complications for those who have the disease. And investment in health-care systems in low- and middle-income countries can help them to adapt to the increasing burden of lifelong diseases such as diabetes.
The cost issue, too, must urgently be addressed. We must tackle deficiencies in distribution systems that limit access to drugs and diagnostics, driving up costs. This will require better forecasting, planning, and distribution; more effective negotiation of prices; and limits on markups.
Moreover, we must invest in research and development of low-cost diabetes treatments and diagnostic tools that are suited for low-resource environments. Smart collaborative projects that bring innovative thinkers from nonprofits, academia, and the private sector together to create effective, affordable, and appropriate solutions are desperately needed.
Diabetes is not unique among NCDs. Essential medicines and technologies for diagnosing and treating heart disease, cancer, and respiratory ailments are also significantly less available and proportionally more expensive for people in low- and middle-income countries than they are for those in the rich world.
This disparity prompted the medical journal The Lancet to call the NCD crisis the “social justice issue of our time”. Unless we take action, the crisis will only become more serious. The WHO expects that, from 2010 to 2020, deaths from NCDs will grow by 15%, with the majority occurring in low- and middle- income countries.
Today, just 1% of all global health financing goes to NCD-related programmes. This imbalance has to change — and fast. Otherwise, the remarkable gains made in improving global health in the last 25 years will be overwhelmed by a rising tide of people who suffer and die from chronic diseases that we know how to prevent and treat.
Steve Davis is president and CEO of the Seattle-based international nonprofit organisation Path.
Copyright: Project Syndicate, 2016.
© Irish Examiner Ltd. All rights reserved